- Conditions
- Metastatic Uveal Melanoma in the Liver
- Interventions
- SD-101, Nivolumab, Ipilimumab, Nivolumab and Relatlimab
- Drug · Biological
- Lead sponsor
- TriSalus Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
- Interventions
- BGB-B3227, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • St Louis, Missouri • Hackensack, New Jersey + 2 more
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Interventions
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- U3-1287, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
- Drug
- Lead sponsor
- Oncomatryx Biopharma S.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
- Interventions
- Elimusertib (BAY1895344), Niraparib
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- AML (Acute Myeloid Leukemia)
- Interventions
- CLN-049, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York • Houston, Texas
- Conditions
- Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- IRX 2, Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Disitamab vedotin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 128
- States / cities
- Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • New York, New York
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
- Drug
- Lead sponsor
- PeptiDream Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- ALXN1830
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
- Conditions
- Prostate Cancer
- Interventions
- PSA/IL-2/GM-CSF
- Biological
- Lead sponsor
- OncBioMune Pharmaceuticals
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Myelogenous Leukemia, Acute
- Interventions
- RO5045377, cytarabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Valhalla, New York • Philadelphia, Pennsylvania • San Antonio, Texas
- Conditions
- COVID
- Interventions
- BM-Allo.MSC, Placebo
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lynwood, California
- Conditions
- Diabetic Foot Infection
- Interventions
- MBN-101, Placebo
- Drug
- Lead sponsor
- Microbion Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Fresno, California • McAllen, Texas
- Conditions
- Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
- Interventions
- Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
- Interventions
- Posaconazole, ABT-199, Decitabine, Azacitidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 13
- States / cities
- Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
- Conditions
- Norovirus Infections
- Interventions
- VXA-GI.1.NN, Placebo Tablet
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Cypress, California • New Orleans, Louisiana • Austin, Texas
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Interventions
- CNP-106, Placebo
- Drug · Other
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Brea, California • Orange, California + 12 more
- Conditions
- Severe Sepsis, Septic Shock
- Interventions
- BMS-936559, Placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Sacramento, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Solid Tumor
- Interventions
- ACTM-838
- Drug
- Lead sponsor
- Actym Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania